Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 2/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.35 |
| ▸ | CEL | P19835 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8390897 | 1.00 | CYP1A2 (0.50) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL2076620 | 0.98 | CYP1A2 (0.46) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL7350448 | 0.93 | SIGMAR1 (0.50) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL97094 | 0.93 | SIGMAR1 (0.50) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL1335898 | 0.93 | SIGMAR1 (0.50) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL8944658 | 0.93 | — | — | |
| SCHEMBL7458663 | 0.91 | SIGMAR1 (0.54) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL7458143 | 0.91 | SIGMAR1 (0.54) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL7452816 | 0.91 | SIGMAR1 (0.54) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL7457536 | 0.91 | SIGMAR1 (0.54) | CYP1A2SIGMAR1EPHX1KDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102947378-A | Clarified polypropylene articles with improved optical properties and/or increased temperature of crystallization | BASF SE | 2013-02-27 | — | — | CN | claimed |
| US-7666866-B2 | Antithrombotic diamides | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | claimed |
| EP-1819693-B1 | ANTITHROMBOTIC DIAMIDES | LILLY CO ELI (US) | 2009-08-26 | — | — | EP | claimed |
| US-20090062271-A1 | Antithrombotic Diamides | ELI LILLY AND COMPANY (US) | 2009-03-05 | — | — | US | claimed |
| EP-1819693-A1 | ANTITHROMBOTIC DIAMIDES | ELI LILLY AND COMPANY (US) | 2007-08-22 | — | — | EP | claimed |
| EP-1301829-A4 | RADIATION SENSITIVE COMPOSITIONS CONTAINING IMAGE QUALITY AND PROFILE ENHANCEMENT ADDITIVES | FUJIFILM ELECTRONIC MATERIALS (US) | 2006-06-28 | — | — | EP | claimed |
| WO-2006057868-A1 | ANTITHROMBOTIC DIAMIDES | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | claimed |
| EP-1516877-A1 | Amine derivatives as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-23 | — | — | EP | claimed |
| US-20040186151-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-23 | — | — | US | claimed |
| WO-2004071448-A2 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | claimed |
| WO-2000055144-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | claimed |
| EP-0983507-A1 | TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES | Trega Biosciences, Inc. (US) | 2000-03-08 | — | — | EP | claimed |
| EP-0977989-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 2000-02-09 | — | — | EP | claimed |
| EP-0923734-A1 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | Trega Biosciences, Inc. (US) | 1999-06-23 | — | — | EP | claimed |
| US-5856556-A | Azetidinone derivatives, a process for their preparation and their use as intermediates in the preparation of carbapenem antibiotics | SANKYO COMPANY, LIMITED (JP) | 1999-01-05 | — | — | US | claimed |
| US-5840500-A | OPIOD RECEPTORS AS ANALGESICS AND CENTRALLY ACTING PAIN KILLERS | TREGA BIOSCIENCES, INC. (US) | 1998-11-24 | — | — | US | claimed |
| WO-1998034115-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| WO-1998034111-A1 | TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| WO-1998002741-A9 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | — | 1998-05-22 | — | — | WO | claimed |
| WO-1998002741-A1 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-01-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062271-A1 | Antithrombotic Diamides | TFPI, SERPINC1, TFPI2 | CYP1A2 936/4885SIGMAR1 4478/4885EPHX1 448/4885 |
| US-20040186151-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | CYP1A2 472/4885SIGMAR1 4632/4885EPHX1 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.